VanEck logo
  • Emerging Markets Equity

    Emerging Markets Rebound as Normalcy Recovers

    David Semple, Portfolio Manager (EME)
     

    Emerging markets are in the process of economic healing despite the uneven impact of COVID-19. Lower rates and higher fiscal spend have created a significant rebound, but at what cost? We strive to isolate the truly exceptional, structural growth companies from the noise and market volatility of ongoing macro events. Additionally, it is worth pointing out that risk aversion has disproportionately affected small- and mid-cap stocks in emerging markets. As markets normalize, we believe it is reasonable to expect relative outperformance from these smaller stocks. As a “true” all capitalization strategy, these changes in sentiment can materially affect the relative performance of our portfolio.

    As the third quarter unfolded, so did the ongoing rebound of emerging markets economies. Easing of virus restrictions, coupled with supportive emerging markets government policies, boosted growth across emerging markets. Indeed, emerging markets governments around the world continued offering fiscal stimuli, including discretionary easing and loan guarantees. Additionally, our expectation is that core emerging markets central banks will maintain their commitments to keep monetary policy accommodative well into 2021.

    China, in particular, has been well positioned for economic recovery in the third quarter and continues to move full steam ahead with gains in investment, industrial production and services activity. Although the country was impacted by the virus first, it took timely and decisive steps to contain its spread and further monitor it through extensive testing, diligent contact tracing and ongoing follow-up. Ultimately, China’s economy benefited from being less dependent on sectors and industries affected by COVID-19, such as international travel and tourism, and more dependent on its export activity, primarily driven by the country’s significant market share in sectors like healthcare and technology. China has achieved a better economic outcome compared to many other emerging and developed market countries, despite the fact that its overall stimuli has been relatively restrained.

    With regards to EM Asia (ex-China), this group is on its way to economic recovery as well. However, COVID-19’s impact is highly divergent across the region. Virus control measures have been lifted for the most part, but the situation remains problematic in some countries. For example, India, Indonesia and the Philippines continue to face increased rates of COVID-19. Domestic activity and regional trade picked up during the quarter, whereas services activity remained well below normal levels.

    Some countries in Latin America have also struggled to control the virus, and unfortunately tend to have a smaller amount of “wiggle room” to address these challenges.

    Emerging Markets Equity Outlook: Looking to a Strong Finish to 2020

    Clearly, we are in extraordinary times. We expect a bumpy first half of 4Q 2020, primarily driven by uncertainty surrounding vaccine news flows, the upcoming U.S. election and somewhat negative investor sentiment towards emerging markets. But, we expect a stronger finish to the year and a more optimistic one year outlook, once vaccines are available, the U.S. election is over and investors feel more confident in the outlook for emerging markets. A key driver of our outlook for the end of 2020 and beyond is an expectation of global growth recovery, boosted by a timely introduction of a COVID-19 vaccine and its distribution schedule.

    The consequences of the global pandemic juxtaposed with truly unprecedented monetary and fiscal stimuli will be with us for many years to come. Emerging markets have traditionally underperformed in a risky environment, but in general, we believe the behavior of the asset class has not been as bad as many might have predicted. A large part of the negative outcome in the first stages of the pandemic was generated by the abnormal strength of the U.S. dollar, driven by a global “shortage” of dollars. Aggressive central bank action has “normalized” the situation, and we continue to have a reasonable hope for U.S. dollar stability (or, dare we say weakness) in the coming quarters. Whilst it may not matter in the shorter term, we think emerging markets currencies are cheap, particularly versus the U.S. dollar. 

    Investing in emerging markets is for the long haul.


  • Important Disclosure

    For informational and advertising purposes only.

    This commentary originates from VanEck Investments Ltd, a UCITS Management Company under Irish law regulated by the Central Bank of Ireland and VanEck Asset Management B.V., a UCITS Management Company under Dutch law regulated by the Netherlands Authority for the Financial Markets. It is intended only to provide general and preliminary information to investors and shall not be construed as investment, legal or tax advice. VanEck Investments Ltd, VanEck Asset Management B.V. and its associated and affiliated companies (together “VanEck”) assume no liability with regards to any investment, divestment or retention decision taken by the investor on the basis of this commentary. The views and opinions expressed are those of the author(s) but not necessarily those of VanEck. Opinions are current as of the commentary’s publication date and are subject to change with market conditions. Certain statements contained herein may constitute projections, forecasts and other forward looking statements, which do not reflect actual results. Information provided by third party sources are believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. All indices mentioned are measures of common market sectors and performance. It is not possible to invest directly in an index.

    All performance information is historical and is no guarantee of future results. Investing is subject to risk, including the possible loss of principal. You must read the Prospectus and KIID before investing in a fund.

    No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.

    © VanEck Investments Ltd / VanEck Asset Management B.V.